Bicycle Therapeutics pioneers bicyclic peptides, or Bicycles, a novel class of chemically synthesised molecules combining biologics' precision with small molecule advantages. Designed to penetrate solid tumours, these constrained therapeutics target cancers resistant to conventional treatments. Founded in 2009 on Nobel Prize-winning research by Sir Greg Winter, Bicycle advances clinical trials in oncology and beyond. Operating from Cambridge, UK and Lexington, Massachusetts, the company develops therapeutics with rapid tissue penetration and tuneable pharmacokinetics that minimise toxicities. Bicycle molecules engage intractable protein targets, addressing unmet medical needs through pharmaceutical partnerships and academic collaborations.
200
Team Members
2009
Founded
Biotechnology
Sector
On-Site
Work Environment
A world where precision-guided therapeutics transform outcomes for patients with solid tumours and diseases once considered intractable to conventional medicine.
At Bicycle, our mission is to create unique, impactful medicines that transform the lives of the largest possible number of patients.
Loading open positions…
Join our team! Explore current opportunities at Bicycle Therapeutics.